Edgestream Partners L.P. Purchases New Position in Krystal Biotech, Inc. $KRYS

Edgestream Partners L.P. acquired a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 19,678 shares of the company’s stock, valued at approximately $2,705,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Brooklyn Investment Group lifted its holdings in shares of Krystal Biotech by 291.7% in the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company’s stock valued at $25,000 after purchasing an additional 105 shares during the last quarter. Hantz Financial Services Inc. lifted its stake in Krystal Biotech by 8,950.0% in the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock valued at $25,000 after buying an additional 179 shares during the last quarter. Twin Tree Management LP acquired a new stake in shares of Krystal Biotech in the first quarter valued at approximately $29,000. First Horizon Advisors Inc. grew its position in shares of Krystal Biotech by 212.8% during the second quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock worth $34,000 after acquiring an additional 166 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its holdings in shares of Krystal Biotech by 128.3% in the 1st quarter. Smartleaf Asset Management LLC now owns 315 shares of the company’s stock valued at $58,000 after acquiring an additional 177 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Stock Up 2.1%

Shares of NASDAQ:KRYS opened at $221.96 on Friday. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $222.66. The firm’s 50-day simple moving average is $196.60 and its 200-day simple moving average is $161.80. The company has a market cap of $6.44 billion, a price-to-earnings ratio of 33.28 and a beta of 0.48.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $1.54. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. The firm had revenue of $97.80 million during the quarter, compared to analysts’ expectations of $93.72 million. On average, research analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Weiss Ratings reiterated a “hold (c+)” rating on shares of Krystal Biotech in a research note on Monday. HC Wainwright reaffirmed a “buy” rating and issued a $240.00 target price on shares of Krystal Biotech in a report on Monday, September 15th. Guggenheim set a $224.00 price target on Krystal Biotech and gave the stock a “buy” rating in a report on Friday, October 17th. Citigroup boosted their price target on Krystal Biotech from $166.00 to $198.00 and gave the company a “neutral” rating in a research report on Tuesday, November 4th. Finally, Bank of America upped their price objective on Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $228.14.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).